

FOI Request re Number of Patients Treated

Please detail the number of Oncology patients treated¹ (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months **January 2018 to December 2018** inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated (regardless of Tumour Type)	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	94	0	0	26	53	15
Nivolumab (Opdivo)	24	Less than 5	Less than 5	Less than 5	6	12
Ipilimumab (Yervoy)	10	0	0	10	0	0
Nivolumab & Ipilimumab	Less than 5	0	0	Less than 5	0	0
Dabrafenib (Tafinlar)	24	0	Less than 5	22	0	0
Cabozantinib (Cabometyx)	7	0	0	0	0	7
Sunitinib (Sutent)	11	0	0	0	0	11
Pazopanib (Votrient)	19	0	0	0	0	19
Axitinib (Inlyta)	Less than 5	0	0	0	0	Less than 5
Atezolizumab (Tecentriq)	21	0	0	0	16	5
Sorafenib (Nexavar)	0	0	0	0	0	0
Tivozanib (Fotivda)	Less than 5	0	0	0	0	Less than 5
Cetuximab (Erbix)	8	8	0	0	0	0
Everolimus (Afinitor)	2	0	0	0	0	Less than 5
Vemurafenib (Zelboraf)	0	0	0	0	0	0
Total Number Treated (all treatments)		11	Less than 5	61	75	73

¹ Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).